Centro Medico Integral de Cancerología CEMIC - Guatemala
Centro Medico Integral de Cancerología CEMIC - Guatemala
Km. 194 Carretera Interamericana Z.0, Salcaja, Quetzaltenango
Select an option
I am a doctor
I am a sponsor
Open studies
Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) - Merck Sharp & Dohme LLCSee more
Esophageal cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Gastric cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Gastroesophageal cancer
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers - HERIZON-GEA-01 - Zymeworks Inc.See more
Lung cancer
Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006) - KEYVIBE-006 - Merck Sharp & Dohme LLCSee more
